Aiming at expanding the therapeutic exploitation of BRCA2-deficiency for cancer therapy, we investigated here whether deleterious BRCA2 mutations might confer increased susceptibility towards TRAIL-R-targeting agents. The gene discussed is BRCA2; the disease is cancer.